BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25669441)

  • 1. Sclerostin and skeletal health.
    Sharifi M; Ereifej L; Lewiecki EM
    Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
    Sebastian A; Loots GG
    Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
    Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
    Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
    Costa AG; Bilezikian JP; Lewiecki EM
    Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
    Pietrzyk B; Smertka M; Chudek J
    Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone and Nutrition. Sclerostin and bone metabolism].
    Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
    Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin: a novel target for intervention in the treatment of osteoporosis.
    Lewiecki EM
    Discov Med; 2011 Oct; 12(65):263-73. PubMed ID: 22031665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis.
    Robinson MK; Caminis J; Brunkow ME
    Drug Discov Today; 2013 Jul; 18(13-14):637-43. PubMed ID: 23579167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.
    Lewiecki EM
    Ther Adv Musculoskelet Dis; 2014 Apr; 6(2):48-57. PubMed ID: 24688605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin deficiency in humans.
    van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
    Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin: therapeutic horizons based upon its actions.
    Costa AG; Bilezikian JP
    Curr Osteoporos Rep; 2012 Mar; 10(1):64-72. PubMed ID: 22234741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin and Bone Aging: A Mini-Review.
    Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
    Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin: from bench to bedside.
    Tanaka S; Matsumoto T
    J Bone Miner Metab; 2021 May; 39(3):332-340. PubMed ID: 33206222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.